A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Ebola Vaccines
Interventions
BIOLOGICAL

cAd3-EBOZ vaccine

BIOLOGICAL

Placebo (for cAd3-EBOZ vaccine)

Diluent

Trial Locations (1)

1011

Clinical Trial Unit Lausanne, Lausanne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Infectious Disease Service, CHUV, Lausanne

UNKNOWN

collaborator

Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

OTHER

collaborator

University of Lausanne Hospitals

OTHER

collaborator

Swiss Tropical & Public Health Institute

OTHER

collaborator

University of Lausanne

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

World Health Organization

OTHER

collaborator

Immunology and Allergy Service, CHUV, Lausanne

UNKNOWN

lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT02289027 - A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland | Biotech Hunter | Biotech Hunter